Diabetes & Metabolism Journal (original) (raw)

Table 1 Baseline demographic and clinical characteristics

Values are presented as mean±standard deviation or number (%). Hypertension is defined as a systolic blood pressure ≥140 mm Hg, or diastolic blood pressure ≥90 mm Hg, or taking anti-hypertensive medication. Dyslipidemia is defined as a total cholesterol ≥240 mg/dL or taking lipid-lowering agents [2].

SGLT2, sodium-glucose cotransporter-2; HbA1c, glycosylated hemoglobin; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; HOMA-β, homeostasis model assessment of β-cell function; HOMA-IR, homeostasis model assessment of insulin resistance; eGFR, estimated glomerular filtration rate; ACEi, ACE inhibitor; ARB, angiotensin II receptor blocker.

Table 2 Changes in measurements after 12 weeks of treatment with sodium-glucose cotransporter-2 inhibitors

Values are presented as mean±standard error.

LS, least square; CI, confidence interval; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate.

aDifference in the LS mean change, which was calculated as add-on therapy minus switch therapy, bP<0.05 from baseline in overall patients and each treatment group, cP<0.05 for the between-treatment group difference.

Table 3 Changes in glycosylated hemoglobin after 12 weeks of treatment with sodium-glucose cotransporter-2 inhibitors as add-on therapy and switch therapy

Values are presented as mean±standard error.

LS, least square; CI, confidence interval; MET, metformin; SU, sulfonylurea; DPP4i, dipeptidyl peptidase 4 inhibitor; TZD, thiazolidinedione.

aDifference in the LS mean change, which was calculated as compared to adding MET in add-on group and switching from DPP4i in switch group, bP<0.05 from baseline in overall patients and each treatment subgroup, cP<0.05 for the between-treatment group difference.

Table 4 Comparison of clinical characteristics between the good responders and the poor responders in overall patients

Values are presented as mean±standard deviation or number (%).

SGLT2, sodium-glucose cotransporter-2; HbA1c, glycosylated hemoglobin; HOMA-β, homeostasis model assessment of β-cell function; HOMA-IR, homeostasis model assessment of insulin resistance; eGFR, estimated glomerular filtration rate.